Stavudine

HIV
Treatment
1 FDA approval
20 Active Studies for Stavudine

What is Stavudine

StavudineThe Generic name of this drug
Treatment SummaryA dideoxynucleoside analog is a type of medication that prevents the virus that causes HIV from replicating. It works by stopping the reverse transcriptase enzyme from making copies of the virus.
Zeritis the brand name
image of different drug pills on a surface
Stavudine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zerit
Stavudine
1994
45

Approved as Treatment by the FDA

Stavudine, commonly known as Zerit, is approved by the FDA for 1 uses including HIV .
HIV
Used in combination with Stavudine to help manage Human Immunodeficiency Virus (HIV) Infections

Effectiveness

How Stavudine Affects PatientsStavudine is a drug used to treat HIV-1. It works by changing the structure of an enzyme called reverse transcriptase, which is used by the virus to replicate. This change prevents the virus from making more copies of itself, blocking its growth. Stavudine is changed into an active form in the body, and it stops the virus from forming a link that is needed for it to make more copies of itself.
How Stavudine works in the bodyStavudine stops HIV from replicating by blocking an enzyme it needs to make copies of itself. This is done by preventing the enzyme from attaching onto a molecule it needs to create a copy.

When to interrupt dosage

The measure of Stavudine is contingent upon the diagnosed issue. The amount of dosage fluctuates, depending on the delivery technique (e.g. Oral or Capsule, gelatin coated - Oral) detailed in the table beneath.
Condition
Dosage
Administration
HIV
15.0 mg, , 20.0 mg, 30.0 mg, 40.0 mg, 1.0 mg/mL, 200.0 mg, 100.0 mg, 75.0 mg, 37.5 mg, 50.0 mg
, Powder, for solution - Oral, Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Powder, for solution, Capsule, Capsule - Oral, Solution, Solution - Oral, For solution - Oral, For solution, Capsule, extended release, Capsule, extended release - Oral

Warnings

There are 20 known major drug interactions with Stavudine.
Common Stavudine Drug Interactions
Drug Name
Risk Level
Description
Acepromazine
Minor
Stavudine may increase the neurotoxic activities of Acepromazine.
Aceprometazine
Minor
Stavudine may increase the neurotoxic activities of Aceprometazine.
Acetophenazine
Minor
Stavudine may increase the neurotoxic activities of Acetophenazine.
Alimemazine
Minor
Stavudine may increase the neurotoxic activities of Alimemazine.
Amineptine
Minor
Stavudine may increase the neurotoxic activities of Amineptine.
Stavudine Toxicity & Overdose RiskStavudine (ZERIT) may cause a tingling, burning, or numbness in the hands and feet, which is a condition known as peripheral neuropathy. Severe cases may lead to lactic acidosis, enlarged and inflamed liver, and even liver failure.
image of a doctor in a lab doing drug, clinical research

Stavudine Novel Uses: Which Conditions Have a Clinical Trial Featuring Stavudine?

Currently, 122 active studies are investigating the utility of Stavudine in the management of Human Immunodeficiency Virus (HIV).
Condition
Clinical Trials
Trial Phases
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1

Stavudine Reviews: What are patients saying about Stavudine?

5Patient Review
3/26/2014
Stavudine for HIV
This treatment really helped me. I'm grateful for modern medicine.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about stavudine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of stavudine?

"The following are symptoms of nerve damage: weakness, numbness, tingling, or burning pain in your hands or feet; nausea, vomiting, diarrhea; rash; or headache."

Answered by AI

Is stavudine an antiviral medication?

"Stavudine is antiviral medicine that is used to treat human immunodeficiency virus (HIV). It can also be used to treat acquired immunodeficiency syndrome (AIDS). However, stavudine is not a cure for either HIV or AIDS. It may also be used for other purposes not mentioned in this guide."

Answered by AI

What is stavudine used for?

"Stavudine is a medication used to treat human immunodeficiency virus (HIV) infection, which is a virus that weakens the immune system and can lead to acquired immunodeficiency syndrome (AIDS). Stavudine is classified as a nucleoside reverse transcriptase inhibitor (NRTI), and it works by decreasing the amount of HIV in the blood."

Answered by AI

Why is stavudine no longer used?

"Although stavudine has similar antiretroviral activity as zidovudine, the significant toxicities associated with stavudine use (e.g. peripheral neuropathy, hyperlactatemia, lactic acidosis, hepatic steatosis, lipoatrophy, and pancreatitis) limit its clinical utility."

Answered by AI

Clinical Trials for Stavudine

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Stavudine clinical trials? We made a collection of clinical trials featuring Stavudine, we think they might fit your search criteria.Go to Trials
Have you considered Stavudine clinical trials? We made a collection of clinical trials featuring Stavudine, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Stavudine clinical trials? We made a collection of clinical trials featuring Stavudine, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security